301301 川宁生物
2025/03 - 三个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)3.58318.84914.2897.4992.361
总资产报酬率 ROA (%)2.70813.5359.1634.1461.149
投入资产回报率 ROIC (%)2.98514.9299.9854.4871.243

边际利润分析
销售毛利率 (%)37.33336.38631.57424.79822.213
营业利润率 (%)27.24329.31023.24914.2686.919
息税前利润/营业总收入 (%)27.57729.93024.43415.9839.649
净利润/营业总收入 (%)22.22224.31919.50010.7713.445

收益指标分析
经营活动净收益/利润总额(%)99.815101.401105.081118.651169.124
价值变动净收益/利润总额(%)-0.046-0.547-1.318-1.8372.898
营业外收支净额/利润总额(%)-0.951-0.756-0.330-11.790-66.783

偿债能力分析
流动比率 (X)2.2392.1281.5601.6721.255
速动比率 (X)1.6481.4390.8991.1610.688
资产负债率 (%)23.53024.98831.22040.22949.508
带息债务/全部投入资本 (%)10.57011.50621.56835.03344.967
股东权益/带息债务 (%)792.543719.585349.970184.124121.635
股东权益/负债合计 (%)324.248299.473219.900148.436101.858
利息保障倍数 (X)46.67435.64019.3744.9641.754

营运能力分析
应收账款周转天数 (天)66.53752.74660.66878.13289.692
存货周转天数 (天)138.907148.326166.893177.739207.786